Lipodystrophy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Lipodystrophy - Pipeline Review, H1 2015', provides an overview of the Lipodystrophy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Lipodystrophy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lipodystrophy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lipodystrophy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lipodystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lipodystrophy Overview 6 Therapeutics Development 7 Pipeline Products for Lipodystrophy - Overview 7 Pipeline Products for Lipodystrophy - Comparative Analysis 8 Lipodystrophy - Therapeutics under Development by Companies 9 Lipodystrophy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Lipodystrophy - Products under Development by Companies 13 Lipodystrophy - Companies Involved in Therapeutics Development 14 Aileron Therapeutics, Inc. 14 Ambrx, Inc. 15 AstraZeneca PLC 16 Bolder Biotechnology, Inc. 17 Theratechnologies Inc. 18 Zydus Cadila Healthcare Limited 19 Lipodystrophy - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 ALRN-5281 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ARX-328 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BBT-031 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 metreleptin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 saroglitazar - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 tesamorelin acetate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Lipodystrophy - Recent Pipeline Updates 39 Lipodystrophy - Dormant Projects 45 Lipodystrophy - Product Development Milestones 46 Featured News & Press Releases 46 May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn 46 May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 46 May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 47 Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 47 Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 48 Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin 49 Jul 08, 2013: Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized 49 Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia 49 Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 50 May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables Number of Products under Development for Lipodystrophy, H1 2015 7 Number of Products under Development for Lipodystrophy - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Lipodystrophy - Pipeline by Aileron Therapeutics, Inc., H1 2015 14 Lipodystrophy - Pipeline by Ambrx, Inc., H1 2015 15 Lipodystrophy - Pipeline by AstraZeneca PLC, H1 2015 16 Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H1 2015 17 Lipodystrophy - Pipeline by Theratechnologies Inc., H1 2015 18 Lipodystrophy - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Lipodystrophy Therapeutics - Recent Pipeline Updates, H1 2015 39 Lipodystrophy - Dormant Projects, H1 2015 45
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.